BRIEF-Arcus Biosciences Announces Clinical Supply Agreement With Aveo Oncology

Arcus Biosciences, Inc.

Arcus Biosciences, Inc.

RCUS

0.00

July 22 (Reuters) - Arcus Biosciences Inc RCUS.N:

  • ARCUS BIOSCIENCES ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH AVEO ONCOLOGY TO EVALUATE CASDATIFAN IN COMBINATION WITH TIVOZANIB FOR ADVANCED KIDNEY CANCER PATIENTS

  • ARCUS BIOSCIENCES - ENROLLMENT FOR NEW ARC-20 COHORT EXPECTED TO BEGIN IN Q4 2026

  • ARCUS BIOSCIENCES - AVEO TO SUPPLY TIVOZANIB; ARCUS TO SPONSOR STUDY; EACH RETAINS RIGHTS TO COMPOUNDS

Source text: ID:nBw8Y6Z5ya

Further company coverage: RCUS.N


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.